<DOC>
	<DOCNO>NCT02953730</DOCNO>
	<brief_summary>The purpose trail study pharmacokinetics Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） Children Adolescents</brief_summary>
	<brief_title>The Study Pharmacokinetics PEG-rhG-CSF Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>1 . Age≤18 year old , gender limit . 2 . Patients acute lymphoblastic leukemia diagnose bone marrow pathology cytology . 3 . Plan receive CAM ( cyclophosphamide , cytarabine,6MP ) chemotherapy regimen . 4 . Previously receive radiotherapy . 5 . Karnofsky Performance Scores ( KPS ) ≥60 . 6 . The expected survival time ＞3 month . 7 . Neutropenia agranulocytosis , bleed tendency . 8 . No significant cardiac dysfunction metabolic disease . 9 . TBIL ( total bilirubin ) , ALT（alanine aminotransferase） , AST（glutamicoxalacetic transaminase） ＜ 2.5×ULN（upper limit normal） . 10 . BUN（blood urine nitrogen），Cr（creatinine），UA（uric acid）＜1.5×ULN . 11 . Written inform consent acquire . 1 . With history systemic radiotherapy . 2 . Infection difficult control , body temperature ≥ 38℃ . 3 . Other situation investigator consider contraindication study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>